

Roberto Rossotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9558560/publications.pdf>

Version: 2024-02-01

22
papers

534
citations

1163117

8
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

1141
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>HIVâ€NAAT</scp> use for early detection of <scp>HIV</scp> infection among highâ€risk men who have sex with men in Italy. HIV Medicine, 2023, 24, 239-241.	2.2	0
2	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCVâ€infected patients treated in a realâ€life setting. Journal of Viral Hepatitis, 2021, 28, 558-568.	2.0	3
3	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0247275.	2.5	7
4	Reply to: Epidemiological evidence for an association between higher influenza vaccine uptake in the elderly and lower COVIDâ€19 deaths in Italy. Journal of Medical Virology, 2021, 93, 2600-2601.	5.0	2
5	Neurological manifestations in patients hospitalized with COVIDâ€19: A retrospective analysis from a large cohort in Northern Italy. European Journal of Neuroscience, 2021, 53, 2912-2922.	2.6	22
6	Interferon-free compared to interferon-based antiviralâ€regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia, 2020, 34, 1462-1466.	7.2	30
7	Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. Journal of Infection, 2020, 81, e11-e17.	3.3	102
8	Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report. Brain, Behavior, and Immunity, 2020, 87, 179-181.	4.1	118
9	Comparison of three therapeutic regimens for genotypeâ€3 hepatitis C virus infection in a large realâ€life multicentre cohort. Liver International, 2020, 40, 769-777.	3.9	15
10	Safety and efficacy of daclatasvir at doses other than 60â€mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalCONA foundation cohorts. Digestive and Liver Disease, 2020, 52, 447-451.	0.9	1
11	Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage. Infectious Diseases, 2019, 51, 714-717.	2.8	2
12	Letter: sustained virological response and liver healing. Alimentary Pharmacology and Therapeutics, 2017, 45, 1171-1173.	3.7	1
13	Electrophysiological Adverse Effects of Direct-Acting Antivirals in Patients With Chronic Hepatitis C. Journal of Clinical Pharmacology, 2017, 57, 931-932.	2.0	0
14	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood, 2016, 128, 2527-2532.	1.4	149
15	Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database. Journal of Clinical Virology, 2016, 83, 48-53.	3.1	5
16	Acute HCV Infection: Diagnosis, Epidemiology and Current Treatment Options. Current Treatment Options in Infectious Diseases, 2015, 7, 113-126.	1.9	0
17	Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. Journal of Hepatology, 2015, 62, 234-237.	3.7	57
18	Rilpivirine resistance and the dangerous liaisons with substitutions at position 184 among patients infected with HIV-1: Analysis from a national drug-resistance database (ARCA). Journal of Medical Virology, 2014, 86, 1459-1466.	5.0	2

#	ARTICLE	IF	CITATIONS
19	Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: A case-control study. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 879-883.	1.5	1
20	Human immunodeficiency virus-1 B and non-B subtypes with the same drug resistance pattern respond similarly to antiretroviral therapy. <i>Clinical Microbiology and Infection</i> , 2012, 18, E66-E70.	6.0	5
21	Clinical management of ESBL-producing Enterobacteriaceae: the insidious role of fluoroquinolones. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 1517-1522.	2.9	8
22	FDG-PET imaging in the diagnosis of HIV-associated multicentric Castleman disease: something is still missing. <i>Topics in Antiviral Medicine</i> , 2012, 20, 116-8.	0.1	4